Emergent BioSolutions Inc
NYSE:EBS
Emergent BioSolutions Inc
NYSE:EBS
Price:
1.93 USD
2.66%
Market Closed
Updated:
May 2, 2024
Section:
Relative Value
The Relative Value of one
EBS
stock under the Base Case scenario is
35.1
USD.
Compared to the current market price of 1.93 USD,
Emergent BioSolutions Inc
is
Undervalued by 95%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
EBS
Relative Value
Base Case
35.1
USD
Undervaluation 95%
Valuation Multiples
Multiples Across Competitors
EBS Competitors Multiples
Emergent BioSolutions Inc Competitors
Emergent BioSolutions Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Emergent BioSolutions Inc
NYSE:EBS
|
100.7m USD | 0.1 | -0.1 | -5.7 | -2.2 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
285.6B USD | 5.3 | 59.3 | 12.9 | 19.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
148.5B USD | 5.3 | 22.1 | 16.4 | 24.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.6B USD | 10.5 | 28.6 | 22.9 | 24 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
98.8B USD | 7.5 | 25 | 16.6 | 18.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133B AUD | 6.1 | 35.1 | 21.3 | 26.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.6B USD | 3 | 168.6 | 6.8 | 8.9 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
42.6B USD | 6.2 | -9 | -9.5 | -8.2 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.5B USD | 3.3 | 27 | 13.8 | 17.3 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.3T KRW | 18.1 | 73.4 | 44.9 | 61.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
